- Home
- IMMP vs MHN Comparison
IMMP vs MHN Comparison
Compare IMMP & MHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- MHN
- Stock Information
- Founded
- IMMP 1987
- MHN 1997
- Country
- IMMP Australia
- MHN United States
- Employees
- IMMP N/A
- MHN N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- MHN Investment Bankers/Brokers/Service
- Sector
- IMMP Health Care
- MHN Finance
- Exchange
- IMMP Nasdaq
- MHN Nasdaq
- Market Cap
- IMMP 211.1M
- MHN N/A
- IPO Year
- IMMP N/A
- MHN N/A
- Fundamental
- Price
- IMMP $1.86
- MHN $10.02
- Analyst Decision
- IMMP Buy
- MHN
- Analyst Count
- IMMP 2
- MHN 0
- Target Price
- IMMP $8.50
- MHN N/A
- AVG Volume (30 Days)
- IMMP 648.0K
- MHN 59.2K
- Earning Date
- IMMP 05-16-2025
- MHN 01-01-0001
- Dividend Yield
- IMMP N/A
- MHN 4.17%
- EPS Growth
- IMMP N/A
- MHN N/A
- EPS
- IMMP N/A
- MHN N/A
- Revenue
- IMMP $3,019,249.00
- MHN N/A
- Revenue This Year
- IMMP $11.25
- MHN N/A
- Revenue Next Year
- IMMP $10.22
- MHN N/A
- P/E Ratio
- IMMP N/A
- MHN N/A
- Revenue Growth
- IMMP 24.11
- MHN N/A
- 52 Week Low
- IMMP $1.32
- MHN $8.69
- 52 Week High
- IMMP $3.34
- MHN $10.81
- Technical
- Relative Strength Index (RSI)
- IMMP 53.43
- MHN 53.46
- Support Level
- IMMP $1.44
- MHN $9.95
- Resistance Level
- IMMP $2.71
- MHN $10.09
- Average True Range (ATR)
- IMMP 0.17
- MHN 0.11
- MACD
- IMMP 0.05
- MHN 0.04
- Stochastic Oscillator
- IMMP 29.75
- MHN 87.27
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.